Agilent Completes Acquisition of Cancer Diagnostics Firm Biocare Medical
A sits 22% above its 52-week low of $108.35.
Summary
Agilent Technologies has completed its acquisition of Biocare Medical, a company specializing in automated staining solutions and reagents for cancer diagnostics. This strategic move expands Agilent's portfolio within the high-growth cancer diagnostics market. While financial terms were not disclosed in this announcement, the completion signifies a concrete step in Agilent's strategy to enhance its life sciences and diagnostics offerings.
At the time of this announcement, A was trading at $131.98 on NYSE in the Life Sciences sector, with a market capitalization of approximately $37.2B. The 52-week trading range was $108.35 to $160.27. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.